Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 6/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804466 | 0.94 | SLC6A9 (0.38) | SLC6A9FFAR4ESR1TSHRPTGDR2 | |
| SCHEMBL19804778 | 0.89 | FFAR4 (0.34) | FFAR4TSHRTHRBALDH1A1CYP3A4 | |
| SCHEMBL19804504 | 0.88 | SLC6A9 (0.39) | SLC6A9FFAR4ESR1TSHRPTGDR2 | |
| SCHEMBL19797045 | 0.87 | PTPN11 (0.34) | SLC6A9ESR1TSHRTHRBPPARG | |
| SCHEMBL19804740 | 0.87 | CYP3A4 (0.41) | SLC6A9FFAR4ESR1PTGDR2PTGDR | |
| SCHEMBL19804503 | 0.84 | SLC6A9 (0.39) | SLC6A9FFAR4ESR1TSHRPTGDR2 | |
| SCHEMBL19796746 | 0.84 | PTPN11 (0.36) | SLC6A9ESR1TSHRTHRBPPARG | |
| SCHEMBL19801619 | 0.83 | SLC6A9 (0.38) | SLC6A9FFAR4ESR1PTGDR2PTGDR | |
| SCHEMBL19804765 | 0.83 | FFAR4 (0.36) | FFAR4TSHRTHRBPPARGMCHR1 | |
| SCHEMBL19804543 | 0.82 | FFAR4 (0.38) | FFAR4TSHRPTGDR2PTGDRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | SLC6A9 2938/4885FFAR4 1715/4885ESR1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.